Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Aatur D. Singhi, MD, PhD

Advertisement

Articles by Aatur D. Singhi, MD, PhD

Aatur D. Singhi, MD, PhD

Dr. Singhi on the Importance of Multidisciplinary Care With Pathologists in Cancer

ByAatur D. Singhi, MD, PhD
January 25th 2022

Aatur D. Singhi, MD, PhD, discusses the importance of facilitating multidisciplinary conversations that include pathologists in cancer care.

Advertisement

Latest Updated Articles

  • Aatur D. Singhi, MD, PhD
    Dr. Singhi on the Importance of Multidisciplinary Care With Pathologists in Cancer

    January 25th 2022



Advertisement
Advertisement

Trending on OncLive

1

Daratumumab Retreatment Displays Activity in Relapsed Myeloma Following Continuous Frontline Therapy

2

QOL, Efficacy, and Cost Considerations Help Drive TKI Treatment Selection in CML

3

Evolving Understanding and Treatment Landscape

4

A Randomized Phase III Study Evaluating Izalontamab Brengitecan (Iza-bren) Versus Physician’s Choice of Chemotherapy in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer (TNBC)

5

frontMIND: Phase 3 Study of Tafasitamab Plus Lenalidomide and R-CHOP for Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us